The Psychedelic Therapy Podcast14 Des 2020

Molly Maloof MD: Dr. Molly’s Ketamine Protocol

Today on the podcast, I'm speaking to Dr. Molly Maloof, a concierge and lifestyle medicine practitioner who has developed a comprehensive protocol for Ketamine-assisted therapy.

On the show, we talk about Molly’s professional journey from burning out in residency to concierge medicine to Stanford professor and Ketamine practitioner. We discuss her protocol in detail and why one shouldn’t try to treat their own depression with street Ketamine. Finally, Dr. Molly gives her advice to new practitioners especially regarding creating a brand in the psychedelic space.

Dr. Molly is a physician, an entrepreneur a medical advisor, a Ketamine practitioner, and a Stanford lecturer. She has advised over 42 companies throughout the world and has lectured extensively. You can catch her with Dr. David Rabin on the Psychedelic News Hour on Fridays on ClubHouse or in the Apple Store as a podcast in January.

Healing is holistic, and it seems like Dr. Molly has thought of everything.

NOTES

TIMESTAMPS

:07 - Dr. Molly’s first experience with psychedelics and her professional journey
:23 - Incorporating spirituality into a medical practice
:30 - Dr. Molly’s ketamine protocol
:41 - Why shouldn’t people use street ketamine to treat their own depression?
:48 - Dr Molly’s advice to upcoming practitioners
:53 - Providing equal access to psychedelic medicine and other issues and opportunities in the Psychedelic Renaissance

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(64)

Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali...

21 Apr 1h 10min

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that...

25 Apr 202555min

Joshua White: Who You Gonna Call? Fireside

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer sup...

13 Feb 20251h 14min

Tom Feegel: Ibogaine for Cognitive Enhancement

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remark...

27 Jan 20251h 6min

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of car...

20 Nov 20241h 4min

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of...

28 Okt 20241h 3min

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, orig...

18 Okt 20241h 9min

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the differe...

8 Aug 202446min